Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CBPO's Cash to Debt is ranked higher than
86% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. CBPO: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CBPO' s Cash to Debt Range Over the Past 10 Years
Min: 0.65  Med: 6.85 Max: No Debt
Current: No Debt
Equity to Asset 0.72
CBPO's Equity to Asset is ranked higher than
55% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CBPO: 0.72 )
Ranked among companies with meaningful Equity to Asset only.
CBPO' s Equity to Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.58 Max: 0.73
Current: 0.72
0.29
0.73
Interest Coverage 293.49
CBPO's Interest Coverage is ranked lower than
69% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBPO: 293.49 )
Ranked among companies with meaningful Interest Coverage only.
CBPO' s Interest Coverage Range Over the Past 10 Years
Min: 6.9  Med: 41.17 Max: 293.49
Current: 293.49
6.9
293.49
F-Score: 7
Z-Score: 14.90
M-Score: -2.40
WACC vs ROIC
15.99%
36.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 42.75
CBPO's Operating margin (%) is ranked higher than
95% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. CBPO: 42.75 )
Ranked among companies with meaningful Operating margin (%) only.
CBPO' s Operating margin (%) Range Over the Past 10 Years
Min: 21.04  Med: 43.5 Max: 50.82
Current: 42.75
21.04
50.82
Net-margin (%) 29.66
CBPO's Net-margin (%) is ranked higher than
92% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. CBPO: 29.66 )
Ranked among companies with meaningful Net-margin (%) only.
CBPO' s Net-margin (%) Range Over the Past 10 Years
Min: 1.86  Med: 25.24 Max: 30.04
Current: 29.66
1.86
30.04
ROE (%) 24.11
CBPO's ROE (%) is ranked higher than
94% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. CBPO: 24.11 )
Ranked among companies with meaningful ROE (%) only.
CBPO' s ROE (%) Range Over the Past 10 Years
Min: 5.04  Med: 29.26 Max: 42.37
Current: 24.11
5.04
42.37
ROA (%) 17.35
CBPO's ROA (%) is ranked higher than
95% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. CBPO: 17.35 )
Ranked among companies with meaningful ROA (%) only.
CBPO' s ROA (%) Range Over the Past 10 Years
Min: 1.84  Med: 16.15 Max: 24.56
Current: 17.35
1.84
24.56
ROC (Joel Greenblatt) (%) 54.77
CBPO's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. CBPO: 54.77 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CBPO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 54.77  Med: 78.88 Max: 197.79
Current: 54.77
54.77
197.79
Revenue Growth (3Y)(%) 17.50
CBPO's Revenue Growth (3Y)(%) is ranked higher than
70% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. CBPO: 17.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CBPO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 8.3  Med: 17.8 Max: 57.4
Current: 17.5
8.3
57.4
EBITDA Growth (3Y)(%) 17.30
CBPO's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CBPO: 17.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CBPO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.5  Med: 25.65 Max: 72.7
Current: 17.3
5.5
72.7
EPS Growth (3Y)(%) 26.40
CBPO's EPS Growth (3Y)(%) is ranked higher than
79% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. CBPO: 26.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CBPO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -12.9  Med: 39.2 Max: 153
Current: 26.4
-12.9
153
» CBPO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CBPO Guru Trades in Q3 2015

Jim Simons 389,100 sh (+21.78%)
Steven Cohen Sold Out
» More
Q4 2015

CBPO Guru Trades in Q4 2015

George Soros 67,700 sh (New)
Paul Tudor Jones 1,868 sh (New)
Jim Simons 377,100 sh (-3.08%)
» More
Q1 2016

CBPO Guru Trades in Q1 2016

George Soros 149,700 sh (+121.12%)
Paul Tudor Jones 1,938 sh (+3.75%)
Matthews Asia Small Companies Fund 44,854 sh (unchged)
Jim Simons 369,700 sh (-1.96%)
» More
Q2 2016

CBPO Guru Trades in Q2 2016

Steven Cohen 31,100 sh (New)
Manning & Napier Advisors, Inc 52,300 sh (New)
George Soros 236,700 sh (+58.12%)
Matthews Asia Small Companies Fund Sold Out
Paul Tudor Jones Sold Out
Jim Simons 229,000 sh (-38.06%)
» More
» Details

Insider Trades

Latest Guru Trades with CBPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:EXEL, NAS:GLPG, OTCPK:BTGGF, NYSE:XON, NAS:JUNO, NAS:RARE, OTCPK:SOLTF, NAS:ACAD, NAS:SRPT, NAS:TECH, NAS:KITE, NAS:ICPT, NAS:BLUE, OTCPK:LBTSF, NAS:ARIA, NAS:NKTR, NAS:IONS, NAS:LGND, OTCPK:ABCZY, NYSE:PBYI » details
Traded in other countries:0CB.Germany, CBPO.Mexico,
China Biologic Products Inc is a biopharmaceutical company that is engaged in the research, development, manufacturing and sales of plasma-based pharmaceutical products to hospitals and inoculation centers directly or through distributors in China.

China Biologic Products Inc was originally incorporated on December 20, 1989 under the laws of the State of Texas as Shepherd Food Equipment, Inc. On November 20, 2000, Shepherd Food Equipment, Inc. changed its corporate name to Shepherd Food Equipment, Inc. Acquisition Corp., which is the survivor of a merger with GRC Holdings, Inc. on May 28, 2003. On January 10, 2007, the Company was converted into a Delaware corporation and changed its name to China Biologic Products, Inc. It is a biopharmaceutical company which is engaged in the research, development, manufacturing and sales of human plasma-based pharmaceutical products in China. The Company has two majority subsidiaries, Shandong Taibang, a company based in Tai'an, Shandong Province and Guizhou Taibang, a company based in Guiyang, Guizhou Province. The Company's products are human albumin and immunoglobulin products. Albumin has been used for almost 50 years to treat critically ill patients by replacing lost fluid and maintaining adequate blood volume and pressure. Immunoglobulin is used for certain disease prevention and treatment by enhancing specific immunity. These products use human plasma as the principal raw material. Human albumin and human immunoglobulin for intravenous injection, or IVIG products, are the top-selling products. The Company sells its products to hospitals and inoculation centers in the PRC directly or through approved distributors.

Ratios

vs
industry
vs
history
P/E(ttm) 36.41
CBPO's P/E(ttm) is ranked lower than
58% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 29.00 vs. CBPO: 36.41 )
Ranked among companies with meaningful P/E(ttm) only.
CBPO' s P/E(ttm) Range Over the Past 10 Years
Min: 2.92  Med: 18.26 Max: 129.2
Current: 36.41
2.92
129.2
PE(NRI) 36.41
CBPO's PE(NRI) is ranked lower than
58% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 36.41 )
Ranked among companies with meaningful PE(NRI) only.
CBPO' s PE(NRI) Range Over the Past 10 Years
Min: 2.92  Med: 18.26 Max: 129.2
Current: 36.41
2.92
129.2
Price/Owner Earnings (ttm) 54.75
CBPO's Price/Owner Earnings (ttm) is ranked lower than
64% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 32.43 vs. CBPO: 54.75 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CBPO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.47  Med: 32.93 Max: 79.77
Current: 54.75
5.47
79.77
P/B 7.58
CBPO's P/B is ranked lower than
76% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. CBPO: 7.58 )
Ranked among companies with meaningful P/B only.
CBPO' s P/B Range Over the Past 10 Years
Min: 0.84  Med: 3.3 Max: 11.71
Current: 7.58
0.84
11.71
P/S 10.52
CBPO's P/S is ranked higher than
54% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. CBPO: 10.52 )
Ranked among companies with meaningful P/S only.
CBPO' s P/S Range Over the Past 10 Years
Min: 0.68  Med: 2.64 Max: 12.74
Current: 10.52
0.68
12.74
PFCF 46.05
CBPO's PFCF is ranked lower than
72% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 28.22 vs. CBPO: 46.05 )
Ranked among companies with meaningful PFCF only.
CBPO' s PFCF Range Over the Past 10 Years
Min: 1.93  Med: 12.85 Max: 66.63
Current: 46.05
1.93
66.63
POCF 25.70
CBPO's POCF is ranked lower than
53% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 23.11 vs. CBPO: 25.70 )
Ranked among companies with meaningful POCF only.
CBPO' s POCF Range Over the Past 10 Years
Min: 1.63  Med: 8.14 Max: 35.59
Current: 25.7
1.63
35.59
EV-to-EBIT 22.69
CBPO's EV-to-EBIT is ranked higher than
52% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 23.97 vs. CBPO: 22.69 )
Ranked among companies with meaningful EV-to-EBIT only.
CBPO' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.2  Med: 6.15 Max: 27.2
Current: 22.69
1.2
27.2
EV-to-EBITDA 21.35
CBPO's EV-to-EBITDA is ranked lower than
53% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CBPO: 21.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBPO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.1  Med: 5.45 Max: 25.5
Current: 21.35
1.1
25.5
PEG 2.06
CBPO's PEG is ranked higher than
53% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 2.18 vs. CBPO: 2.06 )
Ranked among companies with meaningful PEG only.
CBPO' s PEG Range Over the Past 10 Years
Min: 0.42  Med: 1.26 Max: 2.06
Current: 2.06
0.42
2.06
Current Ratio 6.28
CBPO's Current Ratio is ranked higher than
60% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. CBPO: 6.28 )
Ranked among companies with meaningful Current Ratio only.
CBPO' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 2.54 Max: 6.57
Current: 6.28
1.03
6.57
Quick Ratio 4.17
CBPO's Quick Ratio is ranked higher than
50% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. CBPO: 4.17 )
Ranked among companies with meaningful Quick Ratio only.
CBPO' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.63 Max: 4.27
Current: 4.17
0.54
4.27
Days Inventory 389.77
CBPO's Days Inventory is ranked lower than
90% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. CBPO: 389.77 )
Ranked among companies with meaningful Days Inventory only.
CBPO' s Days Inventory Range Over the Past 10 Years
Min: 280.18  Med: 431.83 Max: 490.33
Current: 389.77
280.18
490.33
Days Sales Outstanding 43.09
CBPO's Days Sales Outstanding is ranked higher than
66% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. CBPO: 43.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBPO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.44  Med: 25.92 Max: 43.09
Current: 43.09
2.44
43.09
Days Payable 19.77
CBPO's Days Payable is ranked lower than
78% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. CBPO: 19.77 )
Ranked among companies with meaningful Days Payable only.
CBPO' s Days Payable Range Over the Past 10 Years
Min: 18.05  Med: 39.63 Max: 98.28
Current: 19.77
18.05
98.28

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.10
CBPO's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CBPO: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CBPO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.9  Med: -2.85 Max: 1
Current: 0.1
-5.9
1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 96.67
CBPO's Price/Net Cash is ranked lower than
97% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. CBPO: 96.67 )
Ranked among companies with meaningful Price/Net Cash only.
CBPO' s Price/Net Cash Range Over the Past 10 Years
Min: 15.83  Med: 31.51 Max: 131.59
Current: 96.67
15.83
131.59
Price/Net Current Asset Value 14.30
CBPO's Price/Net Current Asset Value is ranked lower than
77% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. CBPO: 14.30 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CBPO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.4  Med: 11.56 Max: 695
Current: 14.3
2.4
695
Price/Tangible Book 8.05
CBPO's Price/Tangible Book is ranked lower than
69% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. CBPO: 8.05 )
Ranked among companies with meaningful Price/Tangible Book only.
CBPO' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.17  Med: 4.96 Max: 24.6
Current: 8.05
1.17
24.6
Price/Projected FCF 3.23
CBPO's Price/Projected FCF is ranked higher than
52% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.64 vs. CBPO: 3.23 )
Ranked among companies with meaningful Price/Projected FCF only.
CBPO' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.11  Med: 2.57 Max: 3.99
Current: 3.23
1.11
3.99
Price/Median PS Value 3.97
CBPO's Price/Median PS Value is ranked lower than
91% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. CBPO: 3.97 )
Ranked among companies with meaningful Price/Median PS Value only.
CBPO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.33  Med: 0.89 Max: 4.82
Current: 3.97
0.33
4.82
Price/Peter Lynch Fair Value 1.46
CBPO's Price/Peter Lynch Fair Value is ranked higher than
57% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 1.61 vs. CBPO: 1.46 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CBPO' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.51  Med: 1.21 Max: 1.88
Current: 1.46
0.51
1.88
Price/Graham Number 3.61
CBPO's Price/Graham Number is ranked lower than
59% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 2.74 vs. CBPO: 3.61 )
Ranked among companies with meaningful Price/Graham Number only.
CBPO' s Price/Graham Number Range Over the Past 10 Years
Min: 0.43  Med: 1.84 Max: 11.5
Current: 3.61
0.43
11.5
Earnings Yield (Greenblatt) (%) 4.43
CBPO's Earnings Yield (Greenblatt) (%) is ranked higher than
88% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. CBPO: 4.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CBPO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.7  Med: 16.3 Max: 82.6
Current: 4.43
3.7
82.6
Forward Rate of Return (Yacktman) (%) 27.80
CBPO's Forward Rate of Return (Yacktman) (%) is ranked higher than
71% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 14.98 vs. CBPO: 27.80 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CBPO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 19.6  Med: 24.6 Max: 35.3
Current: 27.8
19.6
35.3

More Statistics

Revenue (TTM) (Mil) $324.0
EPS (TTM) $ 3.45
Beta1.94
Short Percentage of Float3.44%
52-Week Range $80.60 - 144.29
Shares Outstanding (Mil)26.89
» More Articles for CBPO

Headlines

Articles On GuruFocus.com
Largest Insiders' Trades of the Week Jun 10 2016 
Insiders Are Selling Facebook and Ford Motor Mar 11 2016 
Weekly CFO Sells Highlight: ULTA, MIND, DG, PSA, CBPO, CNK Dec 20 2011 
Weekly CEO Sells Highlight: CTSH, CBPO, TCB, SRCL Sep 12 2010 

More From Other Websites
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 20 2016
China Biologic Receives CFDA Clinical Trial Approval for Human Coagulation Factor IX Sep 19 2016
China Biologic Receives CFDA Clinical Trial Approval for Human Coagulation Factor IX Sep 19 2016
China Biologic Products, Inc. – Value Analysis (NASDAQ:CBPO) : September 8, 2016 Sep 08 2016
China Biologic Products, Inc. breached its 50 day moving average in a Bullish Manner : CBPO-US :... Sep 07 2016
ETF’s with exposure to China Biologic Products, Inc. : September 6, 2016 Sep 06 2016
Soros, Harvard Make Opposite Bets on China Plasma Company: Chart Aug 31 2016
ETF’s with exposure to China Biologic Products, Inc. : August 25, 2016 Aug 25 2016
China Biologic Products, Inc. breached its 50 day moving average in a Bearish Manner : CBPO-US :... Aug 24 2016
Massive Insider Selling at Northrop Grumman (NOC) and Chinese Biotech, While Insider Buying Observed... Aug 17 2016
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Aug 16 2016
China Biologic Announces Change to Board of Directors Aug 15 2016
China Biologic Announces Change to Board of Directors Aug 15 2016
CHINA BIOLOGIC PRODUCTS, INC. Financials Aug 12 2016
Chinese Plasma Maker China Biologic a Solid Addition for a Portfolio Aug 11 2016
China Biologic Products, Inc.: Leads amongst peers with strong fundamentals Aug 08 2016
China Biologic Products, Inc. :CBPO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 Aug 08 2016
Edited Transcript of CBPO earnings conference call or presentation 5-Aug-16 11:30am GMT Aug 05 2016
China Biologic Products posts 2Q profit Aug 05 2016
China Biologic Products posts 2Q profit Aug 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)